Focused Cognitive Testing in Inpatients

Not Applicable

Terminated

• Conditions: Neurocognitive Disorders
• Interventions: Other: BRAINCHECK

• Registration Number: NCT02826473
• Lead Sponsor: Luzerner Kantonsspital

Brief Summary

Neurocognitive Disorder (NCD) affects over 116'000 people in Switzerland and is frequently unrecognized and underdiagnosed. Because missed and delayed diagnosis are associated with an increased burden of disease health Service Research has prompted a discussion about diagnostic guidelines and screening programs. Some argue that screening for NCD in primary care is the optimal strategy to increase recognition rates; others consider test protocols implemented into hospital admission assessments as more justified. There is no distinct recommendation due to a lack of empirical data on the benefits and harms of cognitive testing yet. This trial strives to fill this gap and provide information about the benefits, harms and the economic case of routine cognitive testing for neurocognitive disorder in high risk elective inpatients, in Switzerland.

The investigators hypothesize that, cognitive tested patients, compared with patients not cognitive tested, will have higher health-related quality of life at 12months; and lower medical health care costs at 18months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-07-05
• Study First Submitted QC: 2016-07-07
• Study First Posted: 2016-07-11
• Study Start: 2017-04-01
• Primary Completion: 2019-05-01
• Study Completion: 2019-05-01
• Status Verified: 2019-12
• Last Update Submitted: 2019-12-10
• Last Update Posted: 2019-12-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Elective inpatients, living in the canton of lucerne, high risk of developing a major neurocognitive disorder, living at home

Read More

Exclusion Criteria

• Known mental disorder according to ICD-10, chapter V, excluding F32 & F33, patients with terminal illness, patients of intensive care unit or oncology patients, no adequate vision or hearing, no ability to speak, write or to understand German, no Informant, antidementia medication

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention-Group	BRAINCHECK	-

Primary Outcome Measures

Name	Time	Method
Health Service Resource Utilization / Costs	every month during 18months	Patient and Caregiver, using Resource Utilization in Dementia (RUD)
Health related quality of life (HRQoL)	every month during 18months	Patient and Caregiver, using EuroQol 5D-5L

Secondary Outcome Measures

Name	Time	Method
prevalence of risk factors associated with developing major neurocognitive disorder within 6 years	baseline/6months	at Hospital Admission, using Brief Dementia Screening Indicator (BDSI)
prevalence of neurocognitive disorder	baseline/6months	at Hospital admission

Trial Locations

Locations (1)

Cantonal Hospital of Lucerne; 🇨🇭 Lucerne, Canton Lucerne, Switzerland